DE LUCA, Giovanna
 Distribuzione geografica
Continente #
NA - Nord America 2.677
EU - Europa 2.219
AS - Asia 1.388
Continente sconosciuto - Info sul continente non disponibili 9
AF - Africa 1
OC - Oceania 1
SA - Sud America 1
Totale 6.296
Nazione #
US - Stati Uniti d'America 2.670
CN - Cina 505
UA - Ucraina 448
IE - Irlanda 435
SG - Singapore 407
GB - Regno Unito 334
TR - Turchia 331
SE - Svezia 276
IT - Italia 197
FR - Francia 174
DE - Germania 153
FI - Finlandia 95
IN - India 91
RU - Federazione Russa 73
VN - Vietnam 33
CZ - Repubblica Ceca 14
IR - Iran 10
BE - Belgio 9
EU - Europa 9
CA - Canada 6
IL - Israele 5
GR - Grecia 4
RS - Serbia 2
AM - Armenia 1
AT - Austria 1
AU - Australia 1
BG - Bulgaria 1
CL - Cile 1
DK - Danimarca 1
EG - Egitto 1
HK - Hong Kong 1
IM - Isola di Man 1
JO - Giordania 1
KR - Corea 1
LB - Libano 1
MX - Messico 1
PH - Filippine 1
RO - Romania 1
Totale 6.296
Città #
Jacksonville 511
Chandler 508
Dublin 431
Singapore 356
Southend 258
Izmir 192
Princeton 188
Nanjing 151
Wilmington 128
Ashburn 106
Beijing 94
Santa Clara 89
Cambridge 84
Dearborn 84
Nanchang 58
Ann Arbor 51
Woodbridge 51
Altamura 45
New York 42
Chieti 34
Dong Ket 33
Jiaxing 29
Houston 26
Boardman 25
Shenyang 25
Norwalk 24
Los Angeles 23
Tianjin 20
Grevenbroich 19
Kunming 19
Washington 17
Hebei 16
Brno 12
Changsha 12
Hangzhou 12
Helsinki 12
Leawood 12
San Mateo 12
Munich 11
Ardabil 10
Augusta 9
Cedar Knolls 9
Jinan 9
Torino 9
Brussels 8
Teramo 8
Campobasso 7
Guangzhou 7
Lanzhou 7
London 7
Monmouth Junction 7
Falls Church 6
Frankfurt am Main 6
Montesilvano Marina 6
Ningbo 6
Pescara 6
Changchun 5
Hanover 5
Orange 5
Taizhou 5
Zhengzhou 5
San Vito Chietino 4
Toronto 4
Borgomanero 3
Florence 3
Milan 3
Mumbai 3
Oxford 3
Pianella 3
Tappahannock 3
Walnut 3
Bangalore 2
Belgrade 2
Benevento 2
Cedar Lake 2
Düsseldorf 2
Fuzhou 2
Hefei 2
Isernia 2
L’Aquila 2
Naples 2
Olomouc 2
Phoenix 2
Rome 2
Seattle 2
Shanghai 2
Somerville 2
Stockholm 2
Amman 1
Andover 1
Antwerp 1
Archi 1
Auburn Hills 1
Basking Ridge 1
Berlin 1
Boston 1
Brooklyn 1
Buffalo 1
Cairo 1
Candiolo 1
Totale 4.050
Nome #
Integrated Lipidomics and Metabolomics Analysis of Tears in Multiple Sclerosis: An Insight into Diagnostic Potential of Lacrimal Fluid 123
IL 13 in multiple sclerosis 120
Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1β levels and expression in peripheral blood mononuclear cells 104
La funzione soppressoria è ridotta nella polineuropatia demielinizzante cronica infiammatoria (CIDP) 97
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 96
Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis 93
Chemokines are Modulated by Interferon beta 1B (IFNT-Beta IB) in Relapsing-Remitting Multiple Sclerosis (RR-MS) 90
Effetti sinergici della terapia con interferone-beta sulla attivazione, adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante/remittente 90
Anti-glycolipid and anti-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy 89
Rantes Levels and mRNA Expression in Relapsing-Remitting Multiple Sclerosis (RR-MS): Effect of interferon Beta 1b (IFNBeta 1b) Treatment 89
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 88
Dysimmune demyelinating polyneuropathies: expression of adhesion molecules in sural nerves and changes in cellular immunity (suppressor cell function and cytokine mRNA expression) induced by treatment (progetto presentato a Telethon) 87
Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. 87
Interferon β1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis 87
Rantes and MCP-1 Secretion by Mononuclear Cells of Patients with Nultiple Sclerosis 86
Increasing age at disability milestones among MS patients in the MSBase Registry 84
Interferon beta1b: the Chieti experience 83
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 83
Effect of TNF intraneural injection into the rat sciatic nerve 82
The Chieti Experience with interferon B1b (IFNB1b) during the first 2 years: Efficacy 82
The Chieti experience with Interferon B1b (IFNB1b) during the first 2 years: side effects. 82
Interferon beta normalizes suppressor cell function in dysimmune neuropathies. 82
MCP-1 expression and secretion in adherent monocyte cultures from multiple sclerosis patients treated with interferon beta-1b 81
Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. 81
Chemokine production by mononuclear cells from relapsing-remitting multiple sclerosis (RR-MS) patients 81
Effects of IL10 on recombinant interferon-beta1b stimulated suppressor cell function in MS and controls subjects 80
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 79
Effect of rhTNF-alpha injection into rat sciatic nerve 79
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 78
Acetylcholine in multiple sclerosis: possible involvement in the modulation of the immune response and in oligodendrocyte recruitment. 78
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 77
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 76
Serum soluble adhesion molecules and proinflammatory cytokines are not increased in chronic inflammatory demyelinating polyneuropathy 76
rlFN-beta-1B stimulated suppressor cell function in multiple sclerosis: effects of anti-IL-10 monoclonal antibody 75
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis 75
OXIDATIVE MODIFICATIONS OF CEREBRAL TRANSTHYRETIN ARE ASSOCIATED WITH MULTIPLE SCLEROSIS 74
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study 74
Effetti sinergici della terapia con interferone-beta sulla attivazione. Adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante /remittente. (C22) 73
Nail loss after teriflunomide treatment: a new potential adverse event 72
Shared T Cell Receptor Usage of Cerebrospinal Fluid Cells in Familial Multiple Sclerosis da: X° National A.I.N.I. Congress Association Italiana Neuroimmunologia - Florence, Italy, November 15/16,1999 71
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 71
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 71
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 71
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 70
Livelli sierici e liquorali di IL13 nella Sclerosi Multipla 69
Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study 69
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 69
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 69
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 67
Effect of rhTNF-a injection into rat sciatic nerve 67
Low dose oral methotrexate (MTX) in chronic progressive (CP) multiple sclerosis (MS) 67
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy 66
CD1A and CD1E gene polymorphisms are associated withsusceptibility to multiple sclerosis 65
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 65
JCV-Ab serostatus in MS patients treated with Natalizumab 65
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 65
Interferone beta1b: bilancio su un gruppo di 30 pazienti 64
IL-13 levels in serum and cerebro-spinal fluid of multiple sclerosis patients 64
Suppressor cell function is decreased in chronic inflammatory demyelinating polyneuropathy 64
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 64
Mononeuropathy following subcutaneous interferon-β injection 63
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 63
Proteomic investigations on differential post-translational modification of transthyretin in multiple sclerosis. 63
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. 62
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 62
Interferon β 1b: The Chieti experience 60
Non-neuronal acetylcholine: a new modulator of immune responses in multiple sclerosis patients. 60
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 57
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 57
Effects of IFN-Beta on rantes and MCP-1 secretion by mononuclear cells frm patients with multiple sclerosis 57
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 57
Evaluation of suppressor cell function in chronicn inflammatory demyelinating polyneuropathy (CIDP) 56
A Multicentre italian study on efficacy and safety of Glatiramer Acetate in multiple sclerosis patients with allergic respiratory diseases 56
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 54
Gestione degli effetti indesiderati della terapia con interferone beta nella sclerosi multipla 53
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. 53
Contribution of metabolomics to multiple sclerosis diagnosis, prognosis and treatment 49
Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients 48
Pregnancy and fetal outcomes after paternal exposure to disease modifying drugs for multiple sclerosis 48
Epilepsy and multiple sclerosis: Clinical, radiological, electrophysiological and neuropsychological aspects 47
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs 47
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 46
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis 45
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society 43
Modulation of the immune response in multiple sclerosis patients: effect of non-neuronal acetylcholine 41
Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases 41
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 40
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. 39
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 37
Efficacy and safety of glatiramer acetate in multiple sclerosis patients with allergicrespiratory diseases. 35
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 34
Pregnancy And Fetal Outcomes After Paternal Exposure To Disease Modifying Drugs For Multiple Sclerosis (P4.157) 33
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis 30
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 22
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose 22
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 13
Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge 12
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 2
Totale 6.433
Categoria #
all - tutte 23.793
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.793


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020624 0 0 0 0 66 92 117 105 16 90 134 4
2020/2021616 86 0 91 1 37 123 1 2 80 68 58 69
2021/2022357 2 4 6 57 11 11 16 34 32 7 54 123
2022/20231.321 104 152 72 158 143 272 81 93 171 17 29 29
2023/2024653 46 30 38 16 37 225 145 30 0 31 5 50
2024/2025799 117 317 334 26 5 0 0 0 0 0 0 0
Totale 6.433